Anthony P. Conley, MD
Department of Sarcoma Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Professor, Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2004 | The University of Texas, Medical Branch, Galveston, Texas, US, MD |
| 2000 | The University of Texas, Pan American, Edinburg, Texas, US, Biology, BS |
Postgraduate Training
| 2010-2011 | Sarcoma Fellowship, Advanced Scholars Program/Willie Tichenor Sarcoma Fellowship, Sarcoma Research, University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2007-2010 | Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2005-2007 | Clinical Residency, Internal Medicine, The University of Texas Health Science Center, Houston, Texas |
| 2004-2005 | Clinical Internship, Internal Medicine, The University of Texas Health Science Center, Houston, Texas |
Licenses & Certifications
| 2025 | Georgia Composite Medical Board |
| 2025 | Mississippi State Board of Medical Licensure |
| 2025 | Oklahoma State Board of Medical Licensure |
| 2025 | Louisiana State Board of Medical Examiners |
| 2025 | Arizona Medical Board |
| 2025 | Washington State Department of Health |
| 2025 | Tennessee Board of Medical Examiners |
| 2025 | Alabama Board of Medical Examiners |
| 2021 | Florida Board of Medicine |
| 2011 | American Board of Internal Medicine, Medical Oncology |
| 2007 | Texas Medical Board |
| 2007 | American Board of Internal Medicine |
Experience & Service
Faculty Academic Appointments
Associate Professor, Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2025
Assistant Professor, Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2019
Assistant Professor, University of South Florida Morsani College of Medicine, Tampa, FL, 2011 - 2012
Instructor, Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2011
Administrative Appointments/Responsibilities
Section Chief, Sarcoma Medical Oncology, UT MD Anderson Cancer Center, 2025 - Present
Assistant Member, Sarcoma, Moffitt Cancer Center, Tampa, FL, 2012 - 2012
Department Lead, Sarcoma Medical Oncology, Moffitt Cancer Center, Tampa, FL, 2011 - 2012
Other Professional Positions
Consultant, Ipsen Biopharmaceuticals, 2024
Consultant, Inhibrx, Inc, San Diego, CA, 2023 - Present
Consultant, Aadi Biosciences, 2022
Member, Outreach Committee, Connective Tissue Oncology Society (CTOS), Houston, 2022 - Present
Member, Data Safety Monitoring Board, CAR-T Solid Tumor Program, University of Pennsylvania, Pennsylvania, 2021 - Present
Scientific Advisory Board, Deciphera Pharmaceuticals, Houston, TX, 2021 - 2024
Consultant, MD Anderson Physician Network, Houston, TX, 2019 - Present
Scientific Advisory Board, Eli Lilly Pharmaceuticals, Houston, TX, 2018
Scientific Advisory Board, Ignyta Pharmaceuticals, Houston, TX, 2017
Member, Early Therapeutics & Rare Cancers Committee, Southwestern Oncology Group (SWOG), Houston, TX, 2016 - Present
Consultant, Nektar Pharmaceuticals, San Francisco, CA, 2016
Consultant, EMD Serano, Rockland, MA, 2015
Member, MD Anderson Site Advisory Panel, Center Trials Support Unit (CTSU), National Cancer Institute, Houston, TX, 2015 - 2018
Consultant, Novartis, East Hanover, NJ, 2015 - 2015
Consultant, EMD Serono, Rockland, MA, 2015
Member, Sarcoma Survivorship Committee, Southwestern Oncology Group (SWOG), Houston, TX, 2015 - 2017
Consultant, Novartis, New Jersey, 2011
Consultant, Novartis, New Jersey, 2011 - 2014
Consultant, Sanofi Aventis, New Jersey, 2011
Intramural Institutional Committee Activities
Vice Chair, Medical Practice Committee, UTMD Anderson Cancer Center, 2025 - Present
Extramural Institutional Committee Activities
Member, AJCC V9 Bone Sarcoma Expert Panel, The University of Texas MD Anderson Cancer Center, 2025 - Present
Guest Clinician & Investigator, NIH Pediatric Chordoma Clinic, NIH, 2025 - Present
Member-Elect, Executive Committee of the Faculty Senate, The University of Texas MD Anderson Cancer Center, 2024
Member, Medical Charts, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2021 - Present
Associate Member, Institutional Review Board 2, The University of Texas MD Anderson Cancer Center, 2021 - 2024
Member, Pharmacy & Therapeutics Committee, University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2017 - 2019
Member, Medical Practice Committee, University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2017 - Present
Ad hoc medical reviewer, CRC, University of Texas MD Anderson, The University of Texas MD Anderson Cancer Center, 2016 - Present
Co-Chairman, Rhabdomyosarcoma Working Group, The University of Texas MD Anderson Cancer Center, 2014 - Present
Member, Mid Level Provider (MLP) Working Group, The University of Texas MD Anderson Cancer Center, 2014 - Present
Medical Oncology Lead, Chondrosarcoma Working Group, The University of Texas MD Anderson Cancer Center, 2012 - Present
Member, Personalized Clinical Trials Group, The University of Texas MD Anderson Cancer Center, 2012 - 2012
Member, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2010
Editorial Activities
Member of Editorial Review Board, The Sarcoma Journal, 2018 - 2020
Review Editor, Frontiers in Immunology, 2017 - Present
Honors & Awards
| 2024 - Present | Top Doctor, Texas Monthly |
| 2023 | Top 10% National Performers, CGCAHPS |
| 2023 | Top Doctor of Houston in Castle Connolly |
| 2022 | Texas Super Doctors |
| 2022 | Top Performer, 1% Nationally Patient Care, Clinical & Group Consumer Assessment of Healthcare Providers & Systems |
| 2018 | Texas Rising Stars, Texas Monthly 06/2018 issue |
| 2018 | Top 10% Performers, CGCAHPS |
| 2011 | Physician of the Year Nominee, Moffitt Cancer Center |
| 2010 | ASCO Cancer Foundation Young Investigator Award, ASCO |
| 2007 | Michelle Miller Rozzell Academic Achievement Award, The University of Texas, Houston |
| 2006 - 2007 | Outstanding Resident of the Year Award, The University of Texas Health Science Center |
| 2005 | Award of Appreciation - Summer Internship for Undergraduate Students in Biomedical Engineering, The University of Texas, MD Anderson Cancer Center |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2014. Sarcomas Integrative Oncology Education Series. Conference. UTMD Anderson Cancer Center. Houston, TX, US.
- 2010. Targeted Therapy of Giant Cell Tumor of Bone. Conference. MD Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2021. Overview of Chondrosarcoma – Biological Landscape and Clinical Implications. Conference. UT MD Anderson Cancer Center. Houston, US.
- 2020. Medical Management of Advanced/Metastatic Chordomas. Conference. UT MD Anderson Cancer Center. Houston, US.
- 2018. Update on the Biology & Treatment of Soft Tissue Sarcomas, Liposarcomas, and Leiomyosarcomas. Conference. UT MD Anderson Cancer Center, US.
- 2018. Immunotherapy for Sarcoma: Are we ready?. Conference. UT MD Anderson Cancer Center, US.
- 2011. Soft Tissue Sarcoma. Conference. 2nd Annual Florida Oncology Symposium. Florida, US.
- 2011. Soft Tissue Sarcoma: Breaking Tradition for Advanced Metastatic Disease. Conference. Watson Clinic, US.
- 2009. GIST Information Support & Therapy Summit. Conference. GIST Support International, US.
National Presentations
- 2020. Patient-reported Outcomes (PROs) From Patients (Pts) with NTRK Fusion-Positive (NTRK-fp) Solid Tumours Receiving Entrectinib in the Global Phase 2 STARTRK-2 Study. Invited. Virtual ESMO Congress 2020 Meeting, US.
- 2017. Systemic Therapies for Chordoma. Invited. Chordoma Foundation/MD Anderson Cancer Center Workshop. Houston, TX, US.
- 2014. PA/ARNP/Allied Health Scientific Session/Osteosarcoma and Chrondrosarcoma. Invited. Musculoskeletal Tissue Society (MSTS). Tampa, FL, US.
- 2012. Scientific Session/Immunotherapy in Sarcomas. Invited. Musculoskeletal Tissue Society (MSTS). Tampa, FL, US.
- 2012. PA/ARNP/Allied Health Scientific Session/Sarcoma Medical Oncology. Invited. Musculoskeletal Tissue Society (MSTS). Houston, TX, US.
International Presentations
- 2025. Primary Localized Chordoma Consensus Guidelines Working Group. Panelist. Milan, IT.
- 2025. Potential Targeted Molecular/Immunotherapies in Clival Chordoma. 34th Annual Meeting & 9th World Congress, US.
- 2024. Adjuvant Therapy Options & Updates - Chordoma. Sacro-Pelvic Tumor Study Group Meeting, US.
- 2024. Adjuvant Therapy Options & Updates - Chondrosarcoma. Sacro-Pelvic Tumor Study Group Meeting, US.
- 2023. A Phase 2 Trial of Cetuximab for Patients with Advanced/Metastatic Chordoma. Invited. Chordoma International Workshop. Boston, US.
- 2021. Oral Abstract Sarcoma Session. Invited. Scientific Program Committee, US.
- 2018. Immunotherapy in Soft Tissue Sarcoma. Invited. Sociedad Mexicana de Oncologia 36th National Congress in Oncology, MX.
- 2018. Advanced Disease. Invited. Chordoma Foundation/International Chordoma Research Workshop. Boston, US.
Grant & Contract Support
| Date: | 2025 - Present |
| Title: | A Phase 1B Study of Brachyury-specific T-Cell Therapy for the Treatment of Patients with Advanced or Refractory Chordoma |
| Funding Source: | Cancer Research Institute (CRI) |
| Role: | Co-PI |
| Date: | 2020 - 2022 |
| Title: | Identification of TCR Targets for Chordoma |
| Funding Source: | Cancer Research Institute |
| Role: | Co-PI |
| ID: | CR13233 |
| Date: | 2020 - 2026 |
| Title: | Texas Experimental Cancer Therapeutics Network - TEX CTN |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | RFA-CA-19-007 |
| Date: | 2016 - 2019 |
| Title: | Early Therapeutics Development with Phase II Emphasis |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | HHSN261201100039C |
| Date: | 2010 - 2011 |
| Title: | Differential MicroRNA Expression and Positron Emission Tomography in Gastrointestinal Stromal Tumors (GIST) After Treatment with Imatinib |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | PI |
| Date: | 2009 |
| Title: | MicroRNA Regulation of Aberrant KIT Signaling in Gastrointestinal Stromal Tumors (GIST) |
| Funding Source: | GIST Cancer Research |
| Role: | Co-PI |
Selected Publications
Invited Articles
- El Beaino M, Roszik J, Livingston JA, Wang WL, Lazar AJ, Amini B, Subbiah V, Lewis V, Conley AP. Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. Curr Oncol Rep 20(5):37, 2018. e-Pub 2018. PMID: 29582189.
Review Articles
- Groisberg R, Roszik J, Conley A, Patel SR, Subbiah V. The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope. Curr Oncol Rep 19(12):78, 2017. e-Pub 2017. PMID: 29030741.
Professional Educational Materials
- Collaborator O. Personalized Cancer Therapy Website, 2014.
Abstracts
- Soewito, S, Lin, HY, Zoghbi, M, Pan, C, Young, P, Araujo, DM, Conley, AP, Livingston, JA, Ludwig, JA, Nakazawa, MS, Ratan, R, Ravi, V, Somaiah, N, Zarzour, MA, Patel, S, Meyer, LA, Soliman, PT, Lyu, H, Nassif, EF, Denu, RA. Doxorubicin-based chemotherapy vs gemcitabine/docetaxel in uterine leiomyosarcoma (ULMS) 43, 2025. e-Pub 2025.
- Lacuna KP, Ingham M, Chen L, Das B, Lee SM, Ge L, Druta M, Conley AP, Keohan ML, Agulnik M, Burgess MA, Chalmers AW, D'Amato GZ, Powers B, Seetharam M, Siontis BL, Pelosof LC, Van Tine BA, Schwartz GK, Weiss MC. Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS). 2024 Annual ASCO Meeting.
- Gingrich A, Beird H, Segura RL, Denu R, Nakazawa M, Ratan R, Livingston J, Zarzour MA, Conley AP, Somaiah N, Araujo DM, Patel S, Roland CL, Futreal A, Lazar AJ, Keung EZ, Nassif Haddad EF, Initiative Team RT, Team PM. Immune infiltrate analysis to reveal distinct immune classes for leiomyosarcomas. 2024 ASCO Annual Meeting.
- Conley AP, Ravi V, Roland CL, Reid TR, Larson C, Caroen S, Williams JA, Oronsky B, Stirn M, Abrouk N, Burbano E, Kennedy LB. Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers. 2024 ASCO Annual Meeting.
- Munnangi P, King BL, Chiang Y, Conley AP, Araujo DM, Livingston J, Ludwig JA, Nakazawa M, Nassif Haddad EF, Ravi V, Ratan R, Zarzour MA, Patel S, Torres KE, Somaiah N. Systemic therapy in NF-1 associated malignant peripheral nerve sheath tumors (MPNST). 2024 ASCO Annual Meeting.
- Nash A, Ratan R, Somaiah N, Conley AP, Lewis VO, Wang WL, Lin HY, Daw NC, Gill JB, Harrison DJ, Gorlick RG, Patel S, Livingston JA. Harmonizing cancer care delivery for AYAs with osteosarcoma: Comparison of pediatric and medical oncology approaches in a single center. 2024 ASCO Annual Meeting.
- Denu RA, Segura RL, Farooqi AS, Ingram D, Wani KM, Cai Y, Torres KE, Keung E, Roland CL, Somaiah N, Ying H, Huse JT, Rai K, Conley AP, Patel S, Wang WL, Lazar AJ, Haddad-Nassif EF. Impact of ATRX loss on survival and immune microenvironment in multiple sarcoma subtypes. 2024 ASCO Annual Meeting.
- Gounder MM, Rosen E, Parikh AR, Conley AP, Hong DS, Sheth S, Mai N, Sgroe E, Mitchell R, Picard R, Brail LH, Cote GM. Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma. 2024 Annual ASCO Meeting.
- Wu X, Ledbetter D, de Almeida RA, Singh S, Conley A, Wang W, Lazar A, Lang F, Gomez-Manzano C, Fueyo J, Alvarez-Breckenridge C. EXTH-67. ONCOLYTIC ADENOVIRAL INFECTION OF CHORDOMA ACHIEVES TREATMENT EFFICACY THROUGH IMMUNOGENIC CELL DEATH AND TUMOR MICROENVIRONMENT ALTERATION. Society for Neuro-Oncology 26(Supplement 8):viii252.
- Thirasastr P, Raj R, Vilson RS, Joseph C, Lin H, Munnangi P, Torres KE, Araujo DM, Nassif Haddad EF, A Zarzour MA, Iyer AV, Pemmanda M, Nakazawa MS, Ludwig JA, Benjamin RS, Conley AP, Livingston A, Patel S, Ratan R, Ravi V, Somaiah N. OUTCOMES OF LATER-LINES SYSTEMIC THERAPIES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST). Connective Tissue Oncology Society.
- Torrado C, Nassif Haddad EF, Nakazawa MS, Araujo DM, Bird JE, Dumbrava EE, Rodon J, Fu S, Hong DS, Lewis VO, Livingston A, Meric-Bernstam F, Patel S, Piha-Paul SA, Ratan R, Ravi V, Somaiah N, Tsimberidou AM, Naing A, Ludwig J, Zarzour MA, Yap TA, Conley AP. NOVEL THERAPEUTICS AND SURROGATE ENDPOINTS IN CHONDROSARCOMA: A RETROSPECTIVE ANALYSIS FROM A PHASE 1 UNIT. Connective Tissue Oncology Society.
- Wannaphut C, Thirasastr P, Nakazawa MS, Araujo DM, Benjamin RS, Conley AP, Livingston A, Ludwig JA, Patel S, Ratan R, Ravi V, A Zarzour MA, Nassif Haddad EF, Somaiah N. Treatment Outcomes of Gemcitabine and DOCETAXEL in Patients with Clear Cell Sarcoma (CCS) OR GASTROINTESTINAL NEUROECTODERMAL TUMOR (GNET): A CASE SERIES. CTOS.
- Grachev D, Ivanov D, Kushnarev V, Yong ST, Kotlov N, Chernyshov K, Bagaev A, Fowler NH, Conley AP, Cote GM, Chawla SP. Transcriptomic analysis of novel tumor suppressor gene fusions in bone sarcomas. 2024 ASCO Annual Meeting.
- Conley AP, Reid T, Larson C, Oronsky B, Caroen S, Stirn M, Burbano E, Abrouk N, Roland CL, Williams J, Kennedy LB. Improved clinical outcomes in patients received treatment beyond tumor progression with AdAPT-001 +/- a checkpoint inhibitor 84.
- Conley AP, Ferry-Galow, Fino KK, Coyne G, Moore N, Sharon E, Burgess M, Chen J, Davis EJ, Merriam P, Razak AR, Vine Tine B, Foster JC, Takebe N, Rosenberger CL, Doroshow JH, Chen AP, Parchment RE. Atezolizumab clinical trial biopsies reveal varied immune landscapes in clear cell sarcoma and chondrosarcoma. AACR Annual Meeting.
Book Chapters
- Livingston JA, Conley AP, Ravi V, Patel SR. In: Chapter 42: Soft tissue and bone sarcomas, The MD Anderson Manual of Medical Oncology, 3rd edition. McGraw Hill, 2022.
- Subbiah V, Roszik J, Conley A. In: Handbook of Targeted Cancer Therapy and Immunotherapy. Wolters Kluwer, 2018.
- Conley AP, Ravi V, Patel S. Targeted Therapy in Solid Tumors: Sarcomas. In: Targeted Therapy in Translational in Cancer Research. John Wiley & Sons, Inc, 2016.
- Livingston JA, Conley A, Ravi V, Patel S. The MD Anderson Manual of Medical Oncology. In: Soft Tissue and Bone Sarcomas. Third. McGraw Hill Medical, 2015.
- Subbiah V, Conley A. In: Sarcoma Chapter. Handbook of Targeted Cancer Therapy. Philadelphia, PA: Wolters Kluwer, 2014.
- Henderson-Jackson E, Conley A, Bui MM. Molecular Pathology of bone and soft tissue neoplasms and potential targets for novel therapy. In: Cancer Growth and Progression. In: Chapter 13. Springer, 2012.
- Conley, AP, Park MS, Trent J, Patel S. Chapter 40: Soft-Tissue and Bone Sarcomas. In: The MD Anderson Manual of Medical Oncology. McGraw Hill Medical, 2010.
Patient Reviews
CV information above last modified September 17, 2026